公开(公告)号：US11926672B2

公开(公告)日：2024-03-12

申请号：US17127629

申请日：2020-12-18

Applicant: Amgen Inc.

Inventor： Xin Yu ,  Jackson Egen ,  Fernando Garces ,  Shunsuke Takenaka ,  AeRyon Kim ,  Deepali Sawant

IPC: C07K16/28 ,  A61P35/04 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61P35/04 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

公开(公告)号：US20230093169A1

公开(公告)日：2023-03-23

申请号：US17793757

申请日：2021-01-22

Applicant: AMGEN RESEARCH (MUNCH) GMBH ,  AMGEN INC.

Inventor： Benno Rattel ,  Matthias Friedrich ,  Oliver Thomas ,  Tara Arvedson ,  Jackson Egen ,  Jason DeVoss ,  Xiaoting Wang ,  Grit Lorenczewski

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K39/395 ,  A61P37/06 ,  A61K38/17 ,  C07K16/24

Abstract: The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is an antagonist of/an inhibitor of signaling, which is based on an interaction of TNF with its cognate receptor (TNFR), wherein the antagonisation or the inhibition of TNF or its cognate receptor prevents, reduces, or blocks TNF/TNFR mediated signalling. Furthermore, the invention provides therapeutic and preventive methods and medical uses of said combination products, as well as a kit comprising said at least one antibody construct and at least one antagonist/inhibitor of TNF or its cognate receptor, wherein the interaction of said antagonist/inhibitor of TNF with its cognate receptor reduces, mitigates, prevents, or treats cytokine release syndrome.